CL2014000134A1 - Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina. - Google Patents

Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina.

Info

Publication number
CL2014000134A1
CL2014000134A1 CL2014000134A CL2014000134A CL2014000134A1 CL 2014000134 A1 CL2014000134 A1 CL 2014000134A1 CL 2014000134 A CL2014000134 A CL 2014000134A CL 2014000134 A CL2014000134 A CL 2014000134A CL 2014000134 A1 CL2014000134 A1 CL 2014000134A1
Authority
CL
Chile
Prior art keywords
protein
psoriasis
tnf
arthritis
diseases
Prior art date
Application number
CL2014000134A
Other languages
English (en)
Spanish (es)
Inventor
Jonathan Henry Ellis
Michael J Molloy
Tejash Shah
Ian M Tomlinson
Ahmed Yasin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44586854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000134(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2014000134A1 publication Critical patent/CL2014000134A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014000134A 2011-07-19 2014-01-17 Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina. CL2014000134A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1112429.4A GB201112429D0 (en) 2011-07-19 2011-07-19 Antigen-binding proteins with increased FcRn binding

Publications (1)

Publication Number Publication Date
CL2014000134A1 true CL2014000134A1 (es) 2014-07-25

Family

ID=44586854

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000134A CL2014000134A1 (es) 2011-07-19 2014-01-17 Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina.

Country Status (22)

Country Link
US (1) US20130243764A1 (https=)
EP (2) EP2734548B1 (https=)
JP (1) JP2014524748A (https=)
KR (1) KR20140054085A (https=)
CN (1) CN103748110A (https=)
AU (1) AU2012285786B2 (https=)
BR (1) BR112014000341A2 (https=)
CA (1) CA2841105A1 (https=)
CL (1) CL2014000134A1 (https=)
CO (1) CO6862106A2 (https=)
CR (1) CR20140029A (https=)
DO (1) DOP2014000007A (https=)
EA (1) EA201391789A1 (https=)
ES (1) ES2600854T3 (https=)
GB (1) GB201112429D0 (https=)
MA (1) MA35345B1 (https=)
MX (1) MX2014000739A (https=)
PE (1) PE20141660A1 (https=)
PH (1) PH12014500167A1 (https=)
SG (1) SG10201601154QA (https=)
WO (1) WO2013011076A2 (https=)
ZA (1) ZA201400062B (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JP2015509526A (ja) 2012-03-07 2015-03-30 カディラ ヘルスケア リミティド 医薬製剤
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158275A1 (en) * 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2013186230A1 (en) * 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
US20160185847A1 (en) * 2012-12-17 2016-06-30 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
FR2999431B1 (fr) * 2012-12-17 2016-03-18 Lfb Biotechnologies Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
BR112015017619A2 (pt) * 2013-01-24 2017-11-21 Glaxosmithkline Ip Dev Ltd formulação líquida, uso de uma formulação, e, kit
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2015007912A1 (en) * 2013-07-19 2015-01-22 Hexal Ag Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3057616B1 (en) * 2013-10-16 2020-03-11 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
PT2946765T (pt) * 2014-05-23 2016-11-10 Ares Trading Sa Composição farmacêutica líquida
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
EA202193002A2 (ru) * 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
US20180016333A1 (en) * 2015-01-28 2018-01-18 Mabxience, S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016189491A1 (en) * 2015-05-28 2016-12-01 Glaxosmithkline Intellectual Property Development Limited Novel formulation
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
CA3011887C (en) 2016-03-14 2024-10-29 Universitetet I Oslo Genetically transformed immunoglobulins with altered FCRN binding
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
US20190185578A1 (en) 2016-07-29 2019-06-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
HRP20260151T1 (hr) 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba
TW202300515A (zh) * 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
ES2933808T3 (es) * 2017-01-11 2023-02-14 Celltrion Inc Fórmula líquida estable
JP6974500B2 (ja) * 2017-01-13 2021-12-01 ハンクス バイオファーマシューティクス，インコーポレイテッド ＦｃＲｎに対するＩｇＧ様抗体の結合親和性を増加し、その血清半減期を延長させる方法
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
US11059892B2 (en) * 2017-08-11 2021-07-13 Research Development Foundation Engineered antibody Fc variants for enhanced serum half life
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
PE20210005A1 (es) 2017-09-29 2021-01-05 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
IL276286B2 (en) * 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life
KR20210137499A (ko) * 2019-03-05 2021-11-17 더 스테이트 오브 이스라엘, 미니스트리 오브 애그리컬처 & 루럴 디벨로프먼트, 애그리컬처럴 리서치 오거니제이션, (에이.알.오.), 볼카니 센터 게놈-편집 조류
CN115770292A (zh) * 2021-09-08 2023-03-10 珠海市丽珠单抗生物技术有限公司 新型冠状病毒SARS-CoV-2的协同免疫及其用途
CN115770291A (zh) * 2021-09-08 2023-03-10 珠海市丽珠单抗生物技术有限公司 新型冠状病毒SARS-CoV-2疫苗加强免疫及其应用
EP4434517A4 (en) * 2021-11-30 2025-06-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-sost antibody pharmaceutical composition and use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
MX336813B (es) * 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
ES2442258T3 (es) * 2006-10-27 2014-02-10 Abbvie Biotechnology Ltd Anticuerpos cristalinos anti-hTNF alfa
ES2840725T3 (es) 2007-08-20 2021-07-07 Glaxo Group Ltd Procedimiento de producción
US20090148905A1 (en) * 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
WO2009073805A2 (en) * 2007-12-04 2009-06-11 Verdezyne, Inc. Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
HRP20150279T1 (hr) * 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
EP2225276B1 (en) * 2007-12-31 2014-04-23 Bayer Intellectual Property GmbH Antibodies to tnf alpha
FR2934599B1 (fr) 2008-07-29 2012-12-21 Arkema France Fabrication de polyethylene a partir de matieres renouvelables, polyethylene obtenu et utilisations
CA2738243C (en) * 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
CA2753287A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
TWI541021B (zh) * 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
US20100278822A1 (en) 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
SG176202A1 (en) * 2009-05-28 2011-12-29 Glaxo Group Ltd Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye.
WO2011074965A1 (en) * 2009-12-17 2011-06-23 Stichting Sanquin Bloedvoorziening Methods and means for counteracting an activity of an fc domain
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations

Also Published As

Publication number Publication date
SG10201601154QA (en) 2016-03-30
EP3009450A1 (en) 2016-04-20
NZ618897A (en) 2016-02-26
EP2734548A2 (en) 2014-05-28
EA201391789A1 (ru) 2014-06-30
GB201112429D0 (en) 2011-08-31
ZA201400062B (en) 2017-08-30
MX2014000739A (es) 2014-02-19
DOP2014000007A (es) 2014-04-30
AU2012285786B2 (en) 2016-05-12
EP2734548B1 (en) 2016-08-17
CN103748110A (zh) 2014-04-23
CO6862106A2 (es) 2014-02-10
CR20140029A (es) 2014-03-05
BR112014000341A2 (pt) 2017-02-14
JP2014524748A (ja) 2014-09-25
KR20140054085A (ko) 2014-05-08
US20130243764A1 (en) 2013-09-19
AU2012285786A1 (en) 2014-02-06
PE20141660A1 (es) 2014-11-21
MA35345B1 (fr) 2014-08-01
WO2013011076A3 (en) 2013-04-04
CA2841105A1 (en) 2013-01-24
WO2013011076A2 (en) 2013-01-24
PH12014500167A1 (en) 2019-03-22
ES2600854T3 (es) 2017-02-13

Similar Documents

Publication Publication Date Title
CL2014000134A1 (es) Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina.
CL2013001625A1 (es) Proteina de union que se une especificamente a tnf-alfa; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad o trastorno asociado a tnf-alfa.
CL2014001054A1 (es) Proteina de enlace que se une al factor de necrosis tumoral alfa (tnf-alfa); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; su uso para tratar un trastorno asociado a tnf-alfa; y metodo para determinar la presencia de tnf-alfa en una muestra.
CL2014000699A1 (es) Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco.
BR112012009854A8 (pt) proteínas de ligação de antígeno il-23 humana
CL2013001975A1 (es) Dominio variable individual de inmunoglobulina anti-tgfbetarii; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica; y su uso para tratar una enfermedad asociada con la señalizacion de tgfbeta.
CL2012002783A1 (es) Proteinas de unión humanizada que se une al factor de necrosis tumoral alfa humano (tnf-alfa); composicion para liberar una proteina que se une a tnf-alfa; construccionde una proteina que puede unirse al tnf-alfa; acido nucleico, vector y celula huesped que comprenden dicha construccion.
MX2016005956A (es) Anticuerpos especificos para fcrn.
TN2014000438A1 (en) Anti-fcrn antibodies
CL2013000566A1 (es) Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
MX372950B (es) Anticuerpos.
EP3034514A4 (en) Antibody specifically binding to glp-1r and fusion protein thereof with glp-1
CL2014003568A1 (es) Células transformadas para producir iduronato-2-sulfatasa (i2s) recombinante; método de producción de i2s recombinante; y proteína i2s recombinante.
CL2015000757A1 (es) Una proteina
CL2011002831A1 (es) Anticuerpo humanizado especifico de la forma protofibrilar del peptido a-beta; uso de dicho anticuerpo para tratar transtornos neurodegenerativos; composicion farmaceutica; celula que produce dichos anticuerpos; y procedimientos de preparacion de dicho anticuerpo.
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CL2013000369A1 (es) Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2013003043A1 (es) Anticuerpos de un único dominio variable dab que se unen a cd40 humano; ácido nucleico que codifica dicho anticuerpo; vector y célula huésped que lo comprenden; composición farmacéutica; uso de dichos anticuerpos para tratar enfermedad inmune.
PL2691416T3 (pl) Białka wiążące podobne do przeciwciał o podwójnym regionie zmiennym mające orientację krzyżową regionu wiążącego
CL2008002444A1 (es) Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
CL2014001217A1 (es) Polinucleotido que codifica un polipeptido de neurotoxina que muestra una menor duracion del efecto biologico en un sujeto; vector; celula huesped; polipeptido codificado; metodo de fabricacion del polipeptido; anticuerpo que se une al polipeptido; y su uso.
CL2011002756A1 (es) Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad.
CL2015001229A1 (es) Método de selección de proteínas ligantes de antígeno her3 humano y que no reaccionan cruzadamente con her4; proteína ligante; anticuerpo ligante de her3; ácido nucleico que lo codifica; célula huésped; método de producción; formulación farmacéutica que lo comprende; uso para tratar el cáncer; y epítopos.
BR112017023131A2 (pt) anticorpos anti- fcrn
CL2013001944A1 (es) Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune.